Vycor Medical Stock Forecast, Price & News

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage that caused by a stroke. It operates in two segments, Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive, computer-based rehabilitation targeted at an un-addressed market of people who have lost their sight as a result of stroke or other brain injury. It offers therapies that restore and compensate for lost vision, including VRT that delivers a series of light stimuli along the border of the patient's visual field loss; Neuro-Eye Therapy (NeET), which targets deep within the blind area by repeated stimulation, allowing patients to detect objects within the blind field; and NeuroEyeCoach, a complementary therapy to VRT and NeET. This segment also provides professional models of VRT and NeuroEyeCoach for physicians; and a clinic-based model comprising NeuroEyeCoach and VIDIT, a diagnostic program that enables therapists to perform high-resolution visual field tests in less than ten minutes. The company primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida.